Marie Tré-Hardy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Marie Tré-Hardy has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Francis Vanderbist
Laboratoire de Chimie biologique et médicale et de Microbiologie pharmaceutique, Institut de Pharmacie, Université Libre de Bruxelles, CP 205/02, Bd. du Triomphe, 1050 Brussels, Belgium,1 Laboratoires SMB, 26-28 rue de la Pastorale, 1080 Brussels, Belgium,2 Laboratory of Bacteriology Research, University of Ghent, Ghent, Belgium3
4 shared publicationsHamidou Traore
Laboratoire de Chimie biologique et médicale et de Microbiologie pharmaceutique, Institut de Pharmacie, Université Libre de Bruxelles, CP 205/02, Bd. du Triomphe, 1050 Brussels, Belgium,1 Laboratoires SMB, 26-28 rue de la Pastorale, 1080 Brussels, Belgium,2 Laboratory of Bacteriology Research, University of Ghent, Ghent, Belgium3
4 shared publicationsMichel Jean Devleeschouwer
3 shared publications- Mario Vaneechoutte
Laboratory Bacteriology Research, Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
2 shared publications Naïma El Manssouri
2 shared publicationsAlain Wilmet
Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium
1 shared publication
Latest Publications
- 1 August 2020
- Published by Elsevier in Journal of Clinical Virology
- Vol. 129, 104472
Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: Experiences of a general hospital
- 1 August 2020
- Published by Elsevier in Journal of Clinical Virology
- Vol. 129, 104472
Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: Experiences of a general hospital
- Open Access
- 17 May 2019
- Published by Springer Nature in BMC Public Health
- Vol. 19 (1) , 597
The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium
Serological surveillance, based on the measurement of the presence of specific antibodies in a given population, can be used in addition to traditional and routine disease surveillance methods. The added value of this has been largely documented for vaccine-preventable diseases, but to a lesser extent for vector-borne diseases. This study aimed to evaluate the utility of seroprevalence data as additional source of information on the epidemiology of Lyme borreliosis in Belgium. In total, 3215 residual blood samples collected in 2013–2015 were analysed with Liaison® Borrelia IgG kit (DiaSorin S.p.A, Saluggia, Italy). Positive and equivocal results were further examined with immunoblotting (recomLine Borrelia IgG kit, Mikrogen, Neuried, Germany). Crude prevalence estimates of equivocal and seropositive results were calculated and further adjusted accounting for clustered sampling and standardized for age, sex and population per province, according to the Belgian population structure in 2014. The effect of age, sex and region on seropositivity was assessed using log-binomial regression. The overall weighted national seroprevalence for Borrelia burgdorferi sensu lato, adjusted for clustered sampling, age, sex and province was 1.06% (95%CI 0.67–1.67). Although not statistically significant, the highest prevalences were observed in men and in those younger than 15 years or older than 59 years of age. At provincial level, the seroprevalence estimates do not follow the geographical distribution of tick bites and diagnoses of Lyme borreliosis as detected through other surveillance systems. Although the use of residual samples for seroprevalence estimates has several advantages, it seems to be a limited tool for serological surveillance of Lyme borreliosis in Belgium, other than follow-up of trends if repeated over time. A population-based sampling strategy might provide a more representative nationwide sample, but would be very time intensive and expensive. Seroprevalence studies within risk groups or risk areas in Belgium could provide a useful alternative approach to complement routine surveillance data of Lyme borreliosis.
- 17 May 2019
- Published by Springer Nature in BMC Public Health
- Vol. 19 (1) , 597
Open AccessThe value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium
Serological surveillance, based on the measurement of the presence of specific antibodies in a given population, can be used in addition to traditional and routine disease surveillance methods. The added value of this has been largely documented for vaccine-preventable diseases, but to a lesser extent for vector-borne diseases. This study aimed to evaluate the utility of seroprevalence data as additional source of information on the epidemiology of Lyme borreliosis in Belgium. In total, 3215 residual blood samples collected in 2013–2015 were analysed with Liaison® Borrelia IgG kit (DiaSorin S.p.A, Saluggia, Italy). Positive and equivocal results were further examined with immunoblotting (recomLine Borrelia IgG kit, Mikrogen, Neuried, Germany). Crude prevalence estimates of equivocal and seropositive results were calculated and further adjusted accounting for clustered sampling and standardized for age, sex and population per province, according to the Belgian population structure in 2014. The effect of age, sex and region on seropositivity was assessed using log-binomial regression. The overall weighted national seroprevalence for Borrelia burgdorferi sensu lato, adjusted for clustered sampling, age, sex and province was 1.06% (95%CI 0.67–1.67). Although not statistically significant, the highest prevalences were observed in men and in those younger than 15 years or older than 59 years of age. At provincial level, the seroprevalence estimates do not follow the geographical distribution of tick bites and diagnoses of Lyme borreliosis as detected through other surveillance systems. Although the use of residual samples for seroprevalence estimates has several advantages, it seems to be a limited tool for serological surveillance of Lyme borreliosis in Belgium, other than follow-up of trends if repeated over time. A population-based sampling strategy might provide a more representative nationwide sample, but would be very time intensive and expensive. Seroprevalence studies within risk groups or risk areas in Belgium could provide a useful alternative approach to complement routine surveillance data of Lyme borreliosis.
- 1 October 2010
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (10) , 4409-4415
Efficacy of the Combination of Tobramycin and a Macrolide in an I n V itro Pseudomonas aeruginosa Mature Biofilm Model
Respiratory disease is the main cause of morbidity and mortality in patients with cystic fibrosis (CF). In particular, patients suffer from chronic infection due to biofilm formation by opportunistic Pseudomonas aeruginosa (32). Therefore, there is an urgent need to develop alternative ways to treat biofilm-associated clinical infections. The aim of this study was to compare the antimicrobial effects in vitro of the combinations tobramycin-clarithromycin and tobramycin-azithromycin against five P. aeruginosa biofilms and to establish the most effective combination. We performed a kinetic study over a period of 28 days of a twice-daily coadministration of the combinations tobramycin-clarithromycin and tobramycin-azithromycin on 12-day-old, mature P. aeruginosa biofilms formed on microplate pegs for 4 clinical isolates and one laboratory strain (PAO1) to simulate the treatment of CF patients with tobramycin inhalation solution (TOBI) through aerosolization. A synergy between tobramycin and clarithromycin was recorded for 3/5 biofilms, with a bacterial decrease of more than 5 log. Conversely, we found an antagonistic activity when 4 μg/ml tobramycin was administered with azithromycin at 2 μg/ml for P. aeruginosa PAO1 and with azithromycin at 2, 20, 50, 100, and 200 μg/ml for P. aeruginosa PYO1. Treatment with tobramycin at 4 μg/ml combined with clarithromycin at 200 μg/ml eradicated all five biofilms, while tobramycin-azithromycin at the same concentrations eradicated only three biofilms. Results of this study suggest that local administration of tobramycin and clarithromycin into the respiratory tract represents a better strategy than the combination tobramycin-azithromycin for the treatment of P. aeruginosa -associated pulmonary infections.
- 1 October 2010
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (10) , 4409-4415
Efficacy of the Combination of Tobramycin and a Macrolide in an I n V itro Pseudomonas aeruginosa Mature Biofilm Model
Respiratory disease is the main cause of morbidity and mortality in patients with cystic fibrosis (CF). In particular, patients suffer from chronic infection due to biofilm formation by opportunistic Pseudomonas aeruginosa (32). Therefore, there is an urgent need to develop alternative ways to treat biofilm-associated clinical infections. The aim of this study was to compare the antimicrobial effects in vitro of the combinations tobramycin-clarithromycin and tobramycin-azithromycin against five P. aeruginosa biofilms and to establish the most effective combination. We performed a kinetic study over a period of 28 days of a twice-daily coadministration of the combinations tobramycin-clarithromycin and tobramycin-azithromycin on 12-day-old, mature P. aeruginosa biofilms formed on microplate pegs for 4 clinical isolates and one laboratory strain (PAO1) to simulate the treatment of CF patients with tobramycin inhalation solution (TOBI) through aerosolization. A synergy between tobramycin and clarithromycin was recorded for 3/5 biofilms, with a bacterial decrease of more than 5 log. Conversely, we found an antagonistic activity when 4 μg/ml tobramycin was administered with azithromycin at 2 μg/ml for P. aeruginosa PAO1 and with azithromycin at 2, 20, 50, 100, and 200 μg/ml for P. aeruginosa PYO1. Treatment with tobramycin at 4 μg/ml combined with clarithromycin at 200 μg/ml eradicated all five biofilms, while tobramycin-azithromycin at the same concentrations eradicated only three biofilms. Results of this study suggest that local administration of tobramycin and clarithromycin into the respiratory tract represents a better strategy than the combination tobramycin-azithromycin for the treatment of P. aeruginosa -associated pulmonary infections.
- 1 January 2009
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 33 (1) , 40-45
Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model
- 1 January 2009
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 33 (1) , 40-45
Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model
- 1 April 2008
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 31 (4) , 329-336
In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures
- 1 April 2008
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 31 (4) , 329-336
In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures